Short Interest in Interpace Biosciences, Inc. (OTCMKTS:IDXG) Drops By 80.7%

Interpace Biosciences, Inc. (OTCMKTS:IDXG) saw a large drop in short interest in the month of August. As of August 14th, there was short interest totaling 91 shares, a drop of 80.7% from the July 30th total of 472 shares. Based on an average trading volume of 17,299 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are sold short.

Interpace Biosciences Stock Performance

Shares of IDXG remained flat at $1.45 on Friday. The stock had a trading volume of 7,104 shares, compared to its average volume of 7,983. The firm has a market cap of $6.42 million, a price-to-earnings ratio of 18.12 and a beta of 0.61. Interpace Biosciences has a 1-year low of $0.77 and a 1-year high of $2.40. The stock’s 50 day moving average is $1.59 and its 200-day moving average is $1.75.

Interpace Biosciences (OTCMKTS:IDXG) last issued its earnings results on Monday, August 10th. The business services provider reported $0.01 EPS for the quarter. The firm had revenue of $9.13 million during the quarter. Interpace Biosciences had a return on equity of 145.40% and a net margin of 67.64%.

Interpace Biosciences Company Profile

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.